<DOC>
	<DOCNO>NCT00548093</DOCNO>
	<brief_summary>To assess antitumor efficacy measure objective response rate oral PF-00299804 take daily , single agent patient advance NSCLC fail least one chemotherapy + erlotinib .</brief_summary>
	<brief_title>PF-00299804 As A Single Agent , In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NonSmall Cell Lung Cancer ( NSCLC ) Prior treatment failure least one regimen chemotherapy erlotinib . Prior treatment two chemotherapy regimen , include adjuvant combine modality treatment . Measurable disease . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Tissue available KRAS/ EGFR test Creatinine clearance &gt; 40 cc/min serum creat &lt; 1.5 x ULN Chemotherapy Radiotherapy Biological investigational agent within 4 week baseline disease assessment . Patients lack tolerance erlotinib therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>previously treat</keyword>
</DOC>